HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Robert Califf, MD, Nominated for FDA Commissioner

The professor of medicine at Duke University School of Medicine previously served as commissioner in 2016.

This content originally appeared on our sister site, HCPLive.

Robert Califf, MD, professor of medicine, Duke University School of Medicine, has been nominated as the next commissioner of the US Food and Drug Administration (FDA).

President Joseph Biden nominated Califf, who formerly ran the agency during the Obama Administration, to replace Acting Commissioner Janet Woodcock, MD. After November 15, Woodcock is legally unable to remain as acting commissioner.

Califf, a cardiologist by trade, was appointed Deputy Commissioner of the FDA Office of Medical Products and Tobacco in 2015, after a 35 year career at Duke University.

In 2016, Califf was confirmed by the US Senate with an 89-4 vote to be the next FDA commissioner after being nominated by President Barack Obama. He served from February 2016 until January 20, 2017.

Woodcock was appointed as acting commissioner following the resignation of Stephen Hahn, MD, at the very end of the Trump administration.

Woodcock previously served as the agency’s Center for Drug Evaluation and Research (CDER) director. She also was a member of the coronavirus 2019 (COVID-19) vaccine response team Operation Warp Speed.